Cited 0 times in
Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2017-02-27T08:07:12Z | - |
dc.date.available | 2017-02-27T08:07:12Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/147092 | - |
dc.description.abstract | PURPOSE: This study analyzed the role of plasma biomarkers for TSU-68 in a previous phase II trial comparing TSU-68 plus docetaxel and docetaxel alone in patients with metastatic breast cancer. MATERIALS AND METHODS: A total of 77 patients were eligible for this study (38 in the TSU-68 plus docetaxel arm and 39 in the docetaxel alone arm). Blood samples were collected prior to the start of each cycle, and vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-AA, -AB, -BB, fibroblast growth factor, M30, C-reactive protein (CRP), and interleukin 6 (IL-6) levels were measured using enzyme linked immunosorbent assay. The primary endpoint was progression-free survival (PFS). RESULTS: In patients with baseline PDGF-AA ≥ median, median PFS was significantly worse in the TSU-68 plus docetaxel group than in the docetaxel alone group (5.4 months vs. 13.7 months, p=0.049), while a trend toward a PFS benefit was observed in those with baseline PDGF-AA < median (9.7 months vs. 4.0 months, p=0.18; p for interaction=0.03). In the TSU-68 plus docetaxel group, PFS showed significant association with fold changes in CRP (p=0.001), IL-6 (p < .001), PDGF-BB (p=0.02), and VEGF (p=0.047) following the first treatment cycle. CONCLUSION: Baseline PDGF-AA levels and dynamics of VEGF, PDGF-BB, CRP, and IL-6 levels were predictive for the efficacy of TSU-68. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 499~507 | - |
dc.language | English, Korean | - |
dc.publisher | Official journal of Korean Cancer Association | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Angiogenesis Inhibitors/administration & dosage | - |
dc.subject.MESH | Angiogenesis Inhibitors/pharmacology* | - |
dc.subject.MESH | Angiogenesis Inhibitors/therapeutic use* | - |
dc.subject.MESH | Antineoplastic Agents/administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents/pharmacology | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols | - |
dc.subject.MESH | Biomarkers, Tumor/blood* | - |
dc.subject.MESH | Breast Neoplasms/blood* | - |
dc.subject.MESH | Breast Neoplasms/drug therapy* | - |
dc.subject.MESH | Breast Neoplasms/pathology | - |
dc.subject.MESH | C-Reactive Protein/analysis | - |
dc.subject.MESH | Enzyme-Linked Immunosorbent Assay | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fibroblast Growth Factors/blood | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Indoles/administration & dosage | - |
dc.subject.MESH | Indoles/pharmacology* | - |
dc.subject.MESH | Indoles/therapeutic use* | - |
dc.subject.MESH | Interleukin-6/blood | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Metastasis/drug therapy* | - |
dc.subject.MESH | Propionates/administration & dosage | - |
dc.subject.MESH | Propionates/pharmacology* | - |
dc.subject.MESH | Propionates/therapeutic use* | - |
dc.subject.MESH | Taxoids/administration & dosage | - |
dc.subject.MESH | Taxoids/pharmacology | - |
dc.subject.MESH | Taxoids/therapeutic use | - |
dc.subject.MESH | Vascular Endothelial Growth Factor A/blood | - |
dc.title | Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer. | - |
dc.type | Article | - |
dc.publisher.location | Korea | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Changhoon Yoo | - |
dc.contributor.googleauthor | Sung-Bae Kim | - |
dc.contributor.googleauthor | Jungsil Ro | - |
dc.contributor.googleauthor | Seock-Ah Im | - |
dc.contributor.googleauthor | Young-Hyuck Im | - |
dc.contributor.googleauthor | Jee Hyun Kim | - |
dc.contributor.googleauthor | Jin-Hee Ahn | - |
dc.contributor.googleauthor | Kyung Hae Jung | - |
dc.contributor.googleauthor | Hong Suk Song | - |
dc.contributor.googleauthor | Seok Yun Kang | - |
dc.contributor.googleauthor | Hee Sook Park | - |
dc.contributor.googleauthor | Hyun-Cheol Chung | - |
dc.identifier.doi | 10.4143/crt.2015.089 | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.relation.journalsince | 2001~ | - |
dc.identifier.pmid | 26194374 | - |
dc.relation.journalbefore | ~2001 Journal of the Korean Cancer Research Association (대한암학회지) | - |
dc.subject.keyword | Angiogenesis | - |
dc.subject.keyword | Biological markers | - |
dc.subject.keyword | Breast neoplasms | - |
dc.subject.keyword | Pharmacology | - |
dc.subject.keyword | TSU-68 | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.citation.volume | 48 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 499 | - |
dc.citation.endPage | 507 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.48(2) : 499-507, 2016 | - |
dc.date.modified | 2017-02-24 | - |
dc.identifier.rimsid | 47124 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.